Xintela AB
1XT
Company Profile
Business description
Xintela AB is a biomedical company that develops stem cell-based treatments with a focus on osteoarthritis and hard-to-heal leg wounds as well as, through the wholly-owned subsidiary Targinta, targeted antibody-based treatments for aggressive cancers such as triple-negative breast cancer and the brain tumor glioblastoma.
Contact
Medicon Village
Lund22381
SWET: +46 462756500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
13
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,006.80 | 116.00 | 1.30% |
| CAC 40 | 7,822.67 | 0.67 | 0.01% |
| DAX 40 | 24,289.51 | 81.42 | -0.33% |
| Dow JONES (US) | 44,342.19 | 142.30 | -0.32% |
| FTSE 100 | 8,992.12 | 19.48 | 0.22% |
| HKSE | 24,825.66 | 326.71 | 1.33% |
| NASDAQ | 20,895.65 | 10.01 | 0.05% |
| Nikkei 225 | 39,819.11 | 82.08 | -0.21% |
| NZX 50 Index | 12,880.40 | 25.01 | -0.19% |
| S&P 500 | 6,296.79 | 0.57 | -0.01% |
| S&P/ASX 200 | 8,757.20 | 118.20 | 1.37% |
| SSE Composite Index | 3,534.48 | 17.66 | 0.50% |